MarketCap
Facebook
X
Telegram
INVO Bioscience Balance Sheet 2025-2010 | INVO
Brief overview of INVO Bioscience's financial position
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets reached $20.2 million, compared with $10.5 million at the beginning. Growth of +93.2% and CAGR near 17.9% show active expansion.
Liabilities expanded faster than the asset base, +311.8% versus +93.2%. Debt-service capacity deserves attention.
The equity ratio is 35.7% versus 69.8% five periods ago. Capitalization remains workable.
The period ended with net cash: net debt stood at -$1.1 million. This supports financial flexibility.
The cash reserve occupies 10.3% of the balance sheet, previously 54.3%. It is one marker of short-term resilience.
The balance sheet includes a negative accumulated result of -$91.4 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
INVO Bioscience's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet INVO Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-1.12 M | 690 K | 3.31 M | 1.42 M | -3.56 M | -9.32 M | -781 K | 183 K | 317 K | 200 K | -271 K | 522 K | 457 K | 468 K | 487 K | - |
Long Term Debt |
745 K | 1.13 M | 3.36 M | 1.35 M | 1.9 M | - | 355 K | - | 132 K | 132 K | - | - | - | - | - | - |
Long Term Debt Current |
209 K | 181 K | 182 K | 160 K | 222 K | 22.7 K | 21.4 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 2.92 M | 4.01 M | - | 132 K | 132 K | - | - | - | - | - | - |
Total Current Liabilities |
10.3 M | 17.9 M | 8 M | 3.34 M | 1.25 M | 2.29 M | 1.5 M | 3.5 M | 5.13 M | 4.77 M | 4.34 M | - | - | - | - | - |
Total Liabilities |
13 M | 26 M | 17.6 M | 4.69 M | 3.16 M | 5.2 M | 5.51 M | 3.5 M | 5.26 M | 4.9 M | 4.34 M | 4.47 M | 3.94 M | 3.5 M | 3.05 M | - |
Deferred Revenue |
722 K | 602 K | 409 K | 120 K | 5.9 K | 714 K | 714 K | 18.9 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-91.4 M | -67.3 M | -57.8 M | -49.8 M | -38.9 M | -32.2 M | -23.9 M | -21.7 M | -18.6 M | -17.9 M | -15.8 M | -10.9 M | -9.13 M | -8.37 M | -7.7 M | - |
Total Assets |
20.2 M | 46.1 M | 18.5 M | 3.71 M | 10.5 M | 10.9 M | 1.8 M | 777 K | 266 K | 286 K | 580 K | 108 K | 123 K | 125 K | 128 K | - |
Cash and Cash Equivalents |
2.08 M | 620 K | 232 K | 90.1 K | 5.68 M | 10.1 M | 1.24 M | 212 K | 25.8 K | 152 K | 492 K | 18.6 K | - | - | - | 12.5 K |
Book Value |
7.22 M | 20 M | 893 K | -978 K | 7.31 M | 5.74 M | -3.71 M | -2.72 M | -4.99 M | -4.62 M | -3.76 M | -4.36 M | -3.81 M | -3.37 M | -2.93 M | - |
Total Shareholders Equity |
7.22 M | 12.6 M | 893 K | -978 K | 7.31 M | 5.74 M | -3.71 M | -2.72 M | -4.99 M | -4.62 M | -3.76 M | -4.36 M | - | - | - | -2.48 M |
All numbers in USD currency
Quarterly Balance Sheet INVO Bioscience
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
660 K | 952 K | 1.04 M | 2.12 M | 1.13 M | 2.25 M | 2.51 M | 3.14 M | 3.36 M | 5.62 M | 3.87 M | 1.61 M | 1.67 M | 1.73 M | 1.79 M | 1.84 M | 1.9 M | 1.33 M | 1.36 M | 52.8 K | 58.6 K | 58.6 K | 58.6 K | 58.6 K | 81.5 K | 81.5 K | 81.5 K | 81.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.63 M | 13 M | 16.7 M | 24.4 M | 26.2 M | 17 M | 16.7 M | 18.3 M | 17.6 M | 19.1 M | 8.34 M | 6.06 M | 5.08 M | 3.39 M | 3.07 M | 2.93 M | 3.16 M | 5.79 M | 5.57 M | 4.59 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.51 M | 5.51 M | 5.51 M | 5.51 M | 3.5 M | 3.5 M | 3.5 M | 5.22 M | 5.26 M | 5.26 M | 5.26 M | 5.26 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.34 M | 4.3 M | 4.34 M | 4.34 M | 4.47 M | 4.34 M | 4.22 M | 4.05 M | 3.94 M | 3.96 M | 3.77 M | 3.72 M | 3.5 M | 3.49 M | 3.28 M | 3.18 M | 3.05 M | 3.06 M | 3.06 M | - |
Deferred Revenue |
725 K | 720 K | 835 K | 725 K | 602 K | 562 K | 417 K | 513 K | 409 K | 230 K | 161 K | 46.7 K | 120 K | 98.7 K | 77.4 K | 5.79 K | 5.9 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 714 K | 18.9 K | 18.9 K | 18.9 K | 18.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-96.9 M | -93.1 M | -90.2 M | -84.9 M | -67.2 M | -63.5 M | -61.9 M | -59.4 M | -57.8 M | -55.8 M | -54.6 M | -52.3 M | -49.8 M | -47 M | -44.5 M | -41.7 M | -38.9 M | -38.7 M | -36.5 M | -34.7 M | -32.2 M | -32.2 M | -32.2 M | -32.2 M | -23.9 M | -23.9 M | -23.9 M | -23.9 M | -21.7 M | -21.7 M | -21.7 M | -21.7 M | -18.6 M | -18.6 M | -18.6 M | -18.6 M | -17.9 M | -17.9 M | -17.9 M | -17.9 M | -15.8 M | -15.6 M | -15.8 M | -15.8 M | -10.9 M | -9.55 M | -9.43 M | -9.24 M | -9.13 M | -8.99 M | -8.77 M | -8.67 M | -8.37 M | -8.32 M | -8.08 M | -7.94 M | -7.7 M | -7.51 M | -7.41 M | - |
Total Assets |
24.7 M | 18.8 M | 19.3 M | 31.7 M | 46.4 M | 17 M | 18 M | 18.3 M | 18.5 M | 19.5 M | 6.64 M | 6.15 M | 4.1 M | 4.68 M | 6.42 M | 8.52 M | 10.5 M | 8.15 M | 9.93 M | 10.2 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 777 K | 777 K | 777 K | 777 K | 266 K | 266 K | 266 K | 266 K | 286 K | 286 K | 286 K | 286 K | 580 K | 199 K | 580 K | 580 K | 108 K | 102 K | 106 K | 115 K | 123 K | 115 K | 115 K | 117 K | 125 K | 140 K | 150 K | 128 K | 128 K | 135 K | 152 K | - |
Cash and Cash Equivalents |
4.9 M | 356 K | 549 K | 840 K | 620 K | 500 K | 900 K | 475 K | 232 K | 1.06 M | 112 K | 2.19 M | 90.1 K | 286 K | 1.96 M | 3.84 M | 5.68 M | 4.71 M | 6.64 M | 8.42 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 1.24 M | 1.24 M | 1.24 M | 1.24 M | 212 K | 212 K | 212 K | 212 K | 25.8 K | 25.8 K | 25.8 K | 25.8 K | 152 K | 152 K | 152 K | 152 K | 492 K | 492 K | 492 K | 492 K | 18.6 K | 6.27 K | 8.63 K | 7.26 K | 18 K | 7.5 K | 2.28 K | 687 | 7.19 K | 27.7 K | 31.5 K | 887 | 403 | 2.24 K | 9.7 K | - |
Book Value |
15 M | 5.85 M | 2.63 M | 7.31 M | 20.2 M | -23.3 K | 1.36 M | 10.2 K | 893 K | 373 K | -1.71 M | 88.5 K | -978 K | 1.29 M | 3.36 M | 5.59 M | 7.31 M | 2.36 M | 4.36 M | 5.6 M | 5.74 M | 5.74 M | 5.74 M | 5.74 M | -3.71 M | -3.71 M | -3.71 M | -3.71 M | -2.72 M | -2.72 M | -2.72 M | -4.44 M | -4.99 M | -4.99 M | -4.99 M | -4.99 M | -4.62 M | -4.62 M | -4.62 M | -4.62 M | -3.76 M | -4.1 M | -3.76 M | -3.76 M | -4.36 M | -4.24 M | -4.12 M | -3.93 M | -3.81 M | -3.84 M | -3.65 M | -3.6 M | -3.37 M | -3.35 M | -3.13 M | -3.05 M | -2.93 M | -2.93 M | -2.9 M | - |
Total Shareholders Equity |
15 M | 5.85 M | 2.63 M | 3.34 M | 12.7 M | -23.3 K | 1.36 M | 10.2 K | 893 K | 373 K | -1.71 M | 88.5 K | -978 K | 1.29 M | 3.36 M | 5.59 M | 7.31 M | 2.36 M | 4.36 M | 5.6 M | 5.74 M | -3.9 M | 5.74 M | 5.74 M | -3.71 M | -3.71 M | -3.71 M | -3.71 M | -2.72 M | -2.72 M | -2.72 M | -2.72 M | -4.99 M | -4.99 M | -4.99 M | -4.99 M | -4.62 M | -4.62 M | -4.62 M | -4.62 M | -3.76 M | -3.76 M | -3.76 M | -3.76 M | -4.36 M | -4.24 M | -4.12 M | -3.93 M | -3.81 M | -3.84 M | -3.65 M | -3.6 M | -3.37 M | -3.35 M | -3.13 M | -3.05 M | -2.93 M | -2.93 M | -2.9 M | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of INVO Bioscience, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.